Extensive exploration of T cell heterogeneity in cancers by single cell sequencing

Xiaofang Wang¹,², Yangqiu Li¹,²

¹Department of Hematology, First Affiliated Hospital, School of Medicine, Jinan University, Guangzhou 510632, China; ²Key Laboratory for Regenerative Medicine of Ministry of Education, Institute of Hematology, School of Medicine, Jinan University, Guangzhou 510632, China

Correspondence to: Yangqiu Li. Key Laboratory for Regenerative Medicine of Ministry of Education, Institute of Hematology, School of Medicine, Jinan University, Guangzhou 510632, China. Email: yangqiuli@hotmail.com.

Abstract

Human T cells are a highly heterogeneous population and can recognize a wide variety of antigens by their T cell receptors (TCRs). Tumor cells display a large repertoire of antigens that serve as potential targets for recognition, thus making T cells in the tumor micro-environment more complicated. Making a connection between TCRs and the transcriptional information of individual T cells will be interesting for investigating clonal expansion within T cell populations under pathologic conditions. Advances in single cell RNA-sequencing (scRNA-seq) have allowed for comprehensive analysis of T cells. In this review, we briefly describe the research progress on tumor micro-environment T cells using single cell RNA sequencing, and then discuss how scRNA-seq can be used to resolve immune system heterogeneity in health and disease. Finally, we point out future directions in this field and potential for immunotherapy.

Keywords: T cells; tumor micro-environment; single-cell RNA-sequencing

Submitted Dec 26, 2018. Accepted for publication Jan 30, 2019.

doi: 10.21147/j.issn.1000-9604.2019.02.15

View this article at: https://doi.org/10.21147/j.issn.1000-9604.2019.02.15

Introduction

Human immune system is composed of multiple cells that coordinately protect against various pathogens. Among these cells, T cells recognize a broad range of self and foreign antigens via a large heterogeneous population of surface antigen receptors, the T cell receptors (TCRs). TCRs vary from cell to cell and represent a sort of “molecular tag” for T cells. T cells are key elements of cancer immunology and T cells found in the tumor microenvironment are named tumor-infiltrating lymphocytes (TILs) (1). In a subset of solid tumors (colorectal cancer, breast cancer, renal cell carcinoma, ovarian cancer, and gastrointestinal stromal cancer), activated CD8⁺ T cells in the tumor microenvironment have positive prognostic value (1-8).

However, increasing data show that T cell tolerance is associated with a failure in antitumor immunity. Firstly, Treg cells prevent cytotoxic T cells activity and promote tumor growth by secreting a volume of T cell suppressive molecules, including IL-10, IL-35, and TGF-β (9,10). Furthermore, TIL cells are regulated by a complex immunosuppressive network, which drives T cells to terminally exhausted T cells (11). T cell exhaustion increase high levels of inhibitory receptors such as programmed cell death protein 1 (PD-1), lymphocyte activation gene 3 protein (LAG-3), cytotoxic T lymphocyte antigen-4 (CTLA-4), and T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain (TIGHT) (12-17). Impaired production of effectors, such as IL-2, TNF-α, TNF-γ, and GzmB, also are demonstrated by exhausted T cells (18). Thus, therapeutic strategies to overcome T cell exhaustion and modulate Tregs are key for solving immune escape by cancers.

The success of cancer immunotherapies based on CTLA-4 or PD-1 blockade has been attributed to the
prevention of T cell exhaustion (19). These treatments have been successful in treating melanoma, lung cancer, and kidney cancer (20,21). However, effective responses have only been observed in a subset of patients and cancer types. The variation in treatment efficacy is linked to the heterogeneity in the immune cell composition of individual tumors in individual patients. It has been reported that significant heterogeneity in the immune composition is observed across tumor subtypes and patients with breast cancer (22). Thus, the question becomes whether T cell state could be an indicator of treatment and prognostic markers. To better define T cell subtypes in tumors, large-scale and high-dimensional analyses are needed.

**Application of single cell RNA-sequencing (scRNA-seq) to study heterogeneous T cells**

Flow cytometry, immunohistochemistry and bulk RNA analysis using a limited number of established markers cannot meet the needs of solving issues surrounding heterogeneity in the T cell composition of individual tumors. scRNA-seq is a powerful technology for resolving heterogeneous cell types and states in human tissues such as the intestine (23,24), brain (25), spleen (26), pancreas (27,28), and blood (29-31). scRNA-seq provides insights into cell functional heterogeneity that were hidden in the bulk cell population. Nowadays, the application of this technique to immune profiling has begun to be realized (32-34). In different tumor micro-environments, different T cell subtypes can be influenced and display several dominant TCR display clones. In addition to transcriptome analysis, the development of scRNA-seq technologies has opened new perspectives for TCR analysis. Studying paired TCR sequences in individual cells will be powerful for understanding the adaptive immune response. Individual phenotypic states are likely shaped by antigenic TCR stimulation and environmental stimuli. Furthermore, TCRs can be used to monitor the dynamics of T cells in tumor immunology (32,35). Thus, making a connection between TCR clonotype composition and the transcriptional landscape of individual T cells will be interesting for investigating the dynamics of clonal expansion within T cell populations under normal or pathologic conditions.

Fluorescence-activated cell sorting (FACS)-purified CD45+CD3+ cell populations are commonly subjected to sequencing. 10X Genomics or SAMRT-seq2 is used to isolate cells and amplify transcripts (36-39). 10X Genomics captures cells using microfluidic devices that trap cells inside a hydrogel. SMART-seq2 relies on FACS into 96-well plates that physically separate one cell from another. Once cells are lysed, sequencing protocols are characterized by a reverse transcription and amplification step before library preparation. The scRNA-seq data generated using 3'/5’ or full-length approaches have been exploited to extract information about T cell properties and heterogeneity. The assembly of full-length (TCR) sequences from scRNA-seq data allows for alpha and beta chain sequence pairing, which is not possible when performing “bulk” analyses, and for the integration of clonality information using the transcriptome of a single T cell (Figure 1). In Table 1, we summarize the methods of scRNA-seq that are used or potential to be used in T cell analysis.

**scRNA-seq of T cells in tumors**

Many research groups have studied transcriptional maps of T cells in different tumors using scRNA-seq. Here, we summarize several pioneering studies that highlight how scRNA-seq can be used for the discovery of T cell cellular states in tumors.

**Breast cancer**

Breast cancer is the most common cancer in women. Although breast cancer has not been considered as a cancer for the application of immunotherapeutic treatments, recent studies have demonstrated evidence that the immune system plays a complex role in breast cancer biology by promoting tumor growth and mediating the eradication of this disease. TILs are significantly increased in a subset of patients, including triple-negative and HER2-positive breast cancers (22,42), making them a prognostic marker for chemotherapy and survival. Recently, researchers from Memorial Sloan Kettering Cancer Center profiled 45,000 immune cells from 8 breast carcinomas and matched normal breast tissue, blood, and lymph nodes. This group derived an immune map of breast cancer, pointing to continuous T cell activation and differentiation states (35). In agreement with previous reports (22,43), these researchers found an activation gradient in CD8+ T cells in tumors. Moreover, T cells in the blood and lymph nodes exhibited varying phenotypes compared with T cells in breast tissue. Tumor-resident T...
Figure 1 Overview of scRNA-seq technology in study of T cells. T cells are usually isolated from tumors using fluorescence-activated cell sorting (FACS). Step 1: Cell isolation. 10X Genomics: first isolate T cells and then capture cells using microfluidic devices that trap cells inside hydrogel droplets; SMART-seq2: isolate individual cells into 96-well plates and profile single-cell transcriptomes separately. Step 2: Amplification method. In this step, T cells are lysed, and reverse transcription and PCR amplification are performed. 10X Genomics uses cellular barcoding techniques and only one PCR reaction, while SMART-seq2 requires the number of PCR reactions to equal to the number of profiled cells. Step 3: Sequencing method. 10X Genomics uses sequencing of the 3'/5' end of each transcript while SMART-seq2 can sequence full-length transcripts. Either can choose to analyze single-cell 5' V(D)J regions. Step 4: Quality control and data analysis.
responses can be obtained in NSCLC when using immune surveillance and may be key targets to enhance immunotherapy and provide exciting avenues for the design of novel therapies.

Liver cancer

Hepatocellular carcinoma (HCC) is the most prevalent tumor type in the liver, and it is often related to chronic hepatitis B virus infection, obesity, or alcohol. However, there are limited treatment options and a lack of clinical success in immunotherapies (56). TILs in HCC are enriched in tumors, while CD4+ and natural killer cells appear to be depleted. Higher cytotoxic activities are curtailed by high checkpoint expression in CD8+ T cells. Cell proliferation pathways were generally lower in TILs and CD8+ T cells; however, there was accordingly increased oxidative phosphorylation and fatty acid oxidation (55). In this case, targeting these pathways may enhance immunotherapy and provide exciting avenues for the design of novel therapies.
characterize the TILs in HCC, Zemin Zhang’s group analyzed greater than 5,000 single T cells isolated from HCC patients and studied their complete TCR sequences and transcriptomes simultaneously (58). A total of 11 unique T cell subtypes, including 5 CD8+ and 6 CD4+ T cell sub-clusters could be distinguished by gene expression. This group found that exhausted CD8+ T cells and Tregs are enriched and clonally expanded in HCC. Primary CD8+ T cells, which overexpress layilin (LAYN), resulted in interferon (IFN)-γ reduction, CD4+ Treg cell suppression, and CD8+ T cell exhaustion as a response. IFN-γ is required for active tumor cell killing, and LAYN is associated with exhausted CD8+ TILs and poor prognosis. Based on the clonal TCR data, it appears that most of the Treg cells in HCC are unique clones, and CD8+ T cells more likely evolve from other types of CD8+ T cells inside HCC tumors. Targeting the layilin pathway may be a potential avenue for HCC treatment in the future.

**Colorectal cancer**

Recent clinical trials have demonstrated that patients with colorectal cancer who display microsatellite instability (MSI) but not microsatellite-stable (MSS) phenotypes respond to the immune-checkpoint blockade of PD-1 (59). Zhang’s group used STARTRAC, an integrated approach of RNA sequencing and TCR tracking, to obtain transcriptomes of 11,138 single T cells from 12 patients with colorectal cancer. They quantitatively analyzed the dynamic relationships among 20 identified T cell subsets with distinct functions and clonalities (60). It showed that both CD8+ effector and “exhausted” T cells exhibited high clonal expansion. Most CD4+ TIL cells and Treg cells showed clonal exclusivity, whereas certain Treg cell clones were linked to several T helper cell clones. It’s noticed that two IFNG+Th1-like cell clusters were identified with distinct IFN-γ-regulating transcription factors. One is the GZMK+ effector memory T cells, which were associated with EOMES and RUNX3. The other is CXCL13+BHLHE40+ Th1-like cell clusters, which were associated with BHLHE40. Only CXCL13+BHLHE40+ Th1-like cells were enriched in colorectal cancer patients with MSI, and this could explain their responses to immune-checkpoint blockade. Furthermore, IGFLR1 was highly expressed in both CXCL13+BHLHE40+Th1-like cells and CD8+ exhausted T cells and possessed co-stimulatory functions. These distinct populations can be used as a resource for T cell exploration and therapeutic targets.

The findings of TILs are summarized in Table 2.

**Conclusions**

Before the development of scRNA-seq, the discovery of new cell subsets involved using cell surface markers. scRNA-seq opens up a new era in which we can now construct a T cell atlas from normal and tumor tissues or cancerous lymph nodes, thus revealing the diversity in the tumor micro-environment, discovering variations in gene expression, and building developmental trajectories. In sum, T cells are heterogeneous in tumors, and Tregs are usually enriched, while CD8+ T cells become exhausted TILs or T_Rm cells in tumors. Anti-inflammatory, exhaustion, hypoxia and anergy genes are up-regulated in these cells, and cancer immunotherapy target genes exhibit distinct expression patterns among the cells. In this manner, different T cell populations could be targeted by different immunotherapies. The T cell composition may be an important biomarker for subtyping tumors and an indicator for patient treatment.

It is important to note that the above-mentioned T cells are αβ T cells, but there is another T cell subtype that occupies 5%–10% of all peripheral T cells in healthy individuals called γδ T cells (61). Unlike αβ T cells, γδ T cells target cancer cells without requiring MHC presentation. γδ T cells have been studied for their therapeutic potential in cancer treatment (62). In this way, taking advantage of scRNA-seq in underlying γδ T cell immune states in tumors is vital for developing strategies for immunotherapies.

Although mouse models have been shown to be useful for understanding immune system effects, scRNA-seq allows for the profiling of human tissues. Furthermore, the diversity of T cells is not only reflected in transcriptome differences, activation state ranges, and TCR clone type diversity, it is also reflected in methylation and chromatin. We anticipate that the development of new technologies will extend single-cell profiling beyond the transcriptome with advances in methylation (63–66), proteome (67), chromatin (68,69), and genome (70) assays. Single-cell multi-omics analysis of individual cells will take place in the near future and help better understand the biology of immune-mediated diseases and monitor immune responses in cancer and post-therapies.
Table 2 Summary of recent study of T cells in tumors using scRNA-seq

| Single-cell method | Cell source | Key findings | Reference |
|--------------------|-------------|--------------|-----------|
| 10X Genomics       | 45,000 immune cells from 8 breast carcinomas and matched normal breast tissue, blood and lymph nodes | T cells reside on continuous activation and differentiation trajectories; Tumor-resident T cells exhibiting the expression of anti-inflammatory, exhaustion, hypoxia and anergy genes | (35) |
| 10X Genomics       | 6,311 CD3⁺CD45⁺ T cells freshly isolated from two samples of human primary TNBC tumor | T<sub>RM</sub> cells express high levels of immune checkpoint molecules and effector proteins; CD8⁺ T<sub>RM</sub> cells contribute to breast cancer immune surveillance and may be key targets for modulating immune checkpoint inhibition | (44) |
| Smart-seq2         | 12,346 T cells from 14 treatment-naive non-small-cell lung cancer patients | A high ratio of “pre-exhausted” to exhausted T cells was associated with better prognosis; Tregs with TNSFSR9 and IL1R2 correlate with poor prognosis | (53) |
| 10X Genomics       | 39,323 T cells originated from lung cancer and 13,375 from non-malignant lungs | CD8⁺ T higher cytotoxic activities are curtailed by high checkpoint expression; CD8⁺ T cells include increased oxidative phosphorylation and fatty acid oxidation | (54) |
| Smart-seq2         | 5,000 single T cells isolated from Hepatocellular carcinoma patients | Exhausted CD8⁺ T cells and Tregs are enriched and clonally expanded; IFN-γ is required for active tumor cell killing, and LAYN is associated with exhausted CD8⁺ TILs and poor prognosis | (58) |
| Smart-seq2         | 11,138 single T cells from 12 patients with colorectal cancer | IFNG⁺TH1-like cell clusters associated with distinct IFN-γ-regulating transcription factors; CXCL13⁺BHLHE40⁺TH1-like cells enriched in patients with microsatellite-instable tumors contribute to responses to immune-checkpoint blockade | (60) |

scRNA-seq, single cell RNA-sequencing; TNBC, triple-negative breast cancer; T<sub>RM</sub>, tissue-resident memory T cells; IFN, interferon; TIL, tumor-infiltrating lymphocytes.

Acknowledgements

This study was supported by grants from the National Natural Science Foundation of China (No. 81770152, 91642111 and 81570143) and the Guangzhou Science and Technology Project (No. 201510010211, 201807010004 and 201803040017).

Footnote

Conflicts of Interest: The authors have no conflicts of interests to declare.

References

1. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313:1960-4.
2. Pagès F, Berger A, Camus M, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005;353:2654-66.
3. Azimi F, Scolyer RA, Rumcheva P, et al. Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J Clin Oncol 2012;30:2678-83.
4. Kreike B, van Kouwenhove M, Horlings H, et al. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 2007;9:R65.
5. Mahmoud SM, Paish EC, Powe DG, et al. Tumor-infiltrating CD8⁺ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 2011;29:1949-55.
6. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348:203-13.
7. Rusakiewicz S, Semeraro M, Sarabi M, et al. Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors. Cancer Res 2013; 73:3499-510.

8. Dong J, Li J, Liu S, et al. Prognostic potential of an immune score based on the density of CD8+ T cells, CD20+ B cells, and CD33+/p-STAT1+ double-positive cells and HMGB1 expression within cancer nests in stage IIIA gastric cancer patients. Chin J Cancer Res 2016;28:543-52.

9. Antony PA, Restifo NP. CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2. J Immunother 2005;28:120-8.

10. Vignali DA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol 2008; 8:523-32.

11. Barber DL, Wherry EJ, Masopust D, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006;439:682-7.

12. Jin HT, Anderson AC, Tan WG, et al. Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. Proc Natl Acad Sci USA 2010;107:14733-8.

13. Fourcade J, Sun Z, Pagliano O, et al. CD8+ T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res 2012;72:887-96.

14. Joller N, Hafler JP, Brynedal B, et al. Cutting edge: TIGIT has T cell-intrinsic inhibitory functions. J Immunol 2011;186:1338-42.

15. Tan J, Chen S, Huang J, et al. Increased exhausted CD8+ T cells with programmed death-1, T-cell immunoglobulin and mucin-domain-containing-3 phenotype in patients with multiple myeloma. Asia Pac J Clin Oncol 2018;14:e266-74.

16. Wherry EJ. T cell exhaustion. Nat Immunol 2011; 12:492-9.

17. Pauken KE, Wherry EJ. Overcoming T cell exhaustion in infection and cancer. Trends Immunol 2015;36:265-76.

18. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 2015;27: 450-61.

19. Song M, Chen X, Wang L, et al. Future of anti-PD-1/PD-L1 applications: Combinations with other therapeutic regimens. Chin J Cancer Res 2018; 30:157-72.

20. Dushyanthen S, Beavis PA, Savas P, et al. Relevance of tumor-infiltrating lymphocytes in breast cancer. BMC Med 2015;13:202.

21. Grun D, Lyubimova A, Kester L, et al. Single-cell messenger RNA sequencing reveals rare intestinal cell types. Nature 2015;525:251-5.

22. Haber AL, Biton M, Rogel N, et al. A single-cell survey of the small intestinal epithelium. Nature 2017;551:333-39.

23. Zeisel A, Munoz-Manchado AB, Codeluppi S, et al. Brain structure. Cell types in the mouse cortex and hippocampus revealed by single-cell RNA-seq. Science 2015;347:1138-42.

24. Jaitin DA, Kenigsberg E, Keren-Shaul H, et al. Massively parallel single-cell RNA-seq for marker-free decomposition of tissues into cell types. Science 2014;343:776-9.

25. Baron M, Veres A, Wolock SL, et al. A single-cell transcriptomic map of the human and mouse pancreas reveals inter- and intra-cell population structure. Cell Syst 2016;3:346-60.

26. Muraro MJ, Dharmadhikari G, Grun D, et al. A single-cell transcriptome atlas of the human pancreas. Cell Syst 2016;3:385-94. e3.

27. Nestorowa S, Hamey FK, Pijuan Sala B, et al. A single-cell resolution map of mouse hematopoietic stem and progenitor cell differentiation. Blood 2016;128:385-94. e3.

28. Karamitros D, Stoilova B, Aboukhalil Z, et al. Single-cell analysis reveals the continuum of human lymphomyeloid progenitor cells. Nat Immunol 2018;19:85-97.
32. Papalexi E, Satija R. Single-cell RNA sequencing to explore immune cell heterogeneity. Nat Rev Immunol 2018;18:35-45.
33. Tirosh I, Izar B, Prakadan SM, et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 2016;352:189-96.
34. Neu KE, Tang Q, Wilson PC, et al. Single-cell genomics: approaches and utility in immunology. Trends Immunol 2017;38:140-9.
35. Azizi E, Carr AJ, Plitas G, et al. Single-cell map of diverse immune phenotypes in the breast tumor microenvironment. Cell 2018;174:1293-308. e36.
36. Zilionis R, Nainys J, Veres A, et al. Single-cell barcoding and sequencing using droplet microfluidics. Nat Protoc 2017;12:44-73.
37. Klein AM, Mazutis L, Akartuna I, et al. Droplet barcoding for single-cell transcriptomics applied to embryonic stem cells. Cell 2015;161:1187-201.
38. Picelli S, Faridani OR, Bjorklund AK, et al. Full-length RNA-seq from single cells using Smart-seq2. Nat Protoc 2014;9:171-81.
39. Macosko EZ, Basu A, Satija R, et al. Highly parallel genome-wide expression profiling of individual cells using nanoliter droplets. Cell 2015;161:1202-14.
40. Guo G, Huss M, Tong GQ, et al. Resolution of cell fate decisions revealed by single-cell gene expression analysis from zygote to blastocyst. Dev Cell 2010;18:675-85.
41. Han X, Wang R, Zhou Y, et al. Mapping the mouse cell atlas by microwell-seq. Cell 2018;172:1091-107.
42. Lin XL, Wang XL, Ma B, et al. HER2-specific T lymphocytes kill both trastuzumab-resistant and trastuzumab-sensitive breast cell lines in vitro. Chin J Cancer Res 2012;24:143-50.
43. Chung W, Eum HH, Lee HO, et al. Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer. Nat Commun 2017;8:15081.
44. Savas P, Virassamy B, Ye C, et al. Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis. Nat Med 2018;24:986-93.
45. Jiang X, Clark RA, Liu L, et al. Skin infection generates non-migratory memory CD8+ T(RM) cells providing global skin immunity. Nature 2012;483:227-31.
46. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 2008;359:1367-80.
47. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
48. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-65.
49. Hellmann MD, Rizvi NA, Goldman JW, et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol 2017;18:31-41.
50. Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014;515:568-71.
51. Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015;348:124-8.
52. Huang AC, Postow MA, Orlowski RJ, et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature 2017;545:60-65.
53. Guo X, Zhang Y, Zheng L, et al. Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing. Nat Med 2018;24:978-85.
54. Lambrechts D, Wauters E, Boeckx B, et al. Phenotype molding of stromal cells in the lung tumor microenvironment. Nat Med 2018;24:1277-89.
55. Zhang Y, Kurupati R, Liu L, et al. Enhancing CD8+ T cell fatty acid catabolism within a metabolically challenging tumor microenvironment increases the efficacy of melanoma immunotherapy. Cancer Cell 2017;32:377-91. e9.
56. Prieto J, Melero I, Sangro B. Immunological landscape and immunotherapy of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2015;12:681-700.
57. Kasper HU, Drebber U, Stippel DL, et al. Liver tumor infiltrating lymphocytes: comparison of hepatocellular and cholangiolar carcinoma. World J Gastroenterol 2009;15:5053-7.
58. Zheng C, Zheng L, Yoo JK, et al. Landscape of infiltrating t cells in liver cancer revealed by single-cell sequencing. Cell 2017;169:1342-56. e16.
59. Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015;372:2509-20.

60. Zhang L, Yu X, Zheng L, et al. Lineage tracking reveals dynamic relationships of T cells in colorectal cancer. Nature 2018;564:268-72.

61. Vantourout P, Hayday A. Six-of-the-best: unique contributions of gammadelta T cells to immunology. Nat Rev Immunol 2013;13:88-100.

62. Paul S, Lal G. Regulatory and effector functions of gamma-delta (gammadelta) T cells and their therapeutic potential in adoptive cellular therapy for cancer. Int J Cancer 2016;139:976-85.

63. Farlik M, Sheffield NC, Nuzzo A, et al. Single-cell DNA methylome sequencing and bioinformatic inference of epigenomic cell-state dynamics. Cell Rep 2015;10:1386-97.

64. Gravina S, Ganapathi S, Vijg J. Single-cell, locus-specific bisulfite sequencing (SLBS) for direct detection of epimutations in DNA methylation patterns. Nucleic Acids Res 2015;43:e93.

65. Guo H, Zhu P, Wu X, et al. Single-cell methylome landscapes of mouse embryonic stem cells and early embryos analyzed using reduced representation bisulfite sequencing. Genome Res 2013;23:2126-35.

66. Smallwood SA, Lee HJ, Angermueller C, et al. Single-cell genome-wide bisulfite sequencing for assessing epigenetic heterogeneity. Nat Methods 2014;11:817-20.

67. Genshaft AS, Li S, Gallant CJ, et al. Multiplexed, targeted profiling of single-cell proteomes and transcriptomes in a single reaction. Genome Biol 2016;17:188.

68. Buenrostro JD, Wu B, Litzenburger UM, et al. Single-cell chromatin accessibility reveals principles of regulatory variation. Nature 2015;523:486-90.

69. Cusanovich DA, Daza R, Adey A, et al. Multiplex single cell profiling of chromatin accessibility by combinatorial cellular indexing. Science 2015;348:910-4.

70. Chen C, Xing D, Tan L, et al. Single-cell whole-genome analyses by Linear Amplification via Transposon Insertion (LIANTI). Science 2017;356:189-94.